透明质酸酶（绵羊）(Hyaluronidase) - 药物靶点：Hyaluronic acid_在研适应症：尿道疾病_专利_临床

概要

基本信息

药物类型

酶

别名

Hyalase、Hyaluronidase (glycoprotein, sheep testis isoenzyme)、Hyaluronidase (ovine)

+ [7]

靶点

Hyaluronic acid

作用机制

透明质酸调节剂

治疗领域

泌尿生殖系统疾病

在研适应症

尿道疾病

非在研适应症

糖尿病性视网膜病变药物过敏反应非增殖性糖尿病视网膜病变+ [3]

原研机构

Bausch & Lomb, Inc.

在研机构

Bausch & Lomb, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2004-05-05),

尿道疾病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 453129440

来源: *****

关联

36

项与透明质酸酶（绵羊）相关的临床试验

IRCT20240827062876N1 / Suspended临床3期IIT

Comparison of two doses of hyaluronidase in the outcome of epidural steroid injection in patients with failed back surgery syndrome

开始日期2024-11-20

申办/合作机构-

NCT06337318 / Recruiting临床3期IIT

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

开始日期2024-10-23

申办/合作机构

National Cancer Institute

CTRI/2024/09/073495 / Not yet recruitingN/AIIT

Effective of hyaluronidase as an adjuvant to bupivaciane for ultrasound guided pericapsular nerve group block in patient positioning for central neuraxial blockade: a randomised double-blind study. - NIL

开始日期2024-09-16

申办/合作机构-

100 项与透明质酸酶（绵羊）相关的临床结果

登录后查看更多信息

100 项与透明质酸酶（绵羊）相关的转化医学

登录后查看更多信息

100 项与透明质酸酶（绵羊）相关的专利（医药）

登录后查看更多信息

4,467

项与透明质酸酶（绵羊）相关的文献（医药）

2024-12-31·mAbs

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo

Article

作者: Liu, Yu ; Wu, Peican ; Lou, Junwen ; Liu, Chendan ; Fang, Xin ; Tang, Yao ; Xu, Yunxia ; Wang, Zheng ; Hu, Ying ; Lu, Lin ; Liu, Yanjun ; Wang, Jinhua ; Lv, Baojie ; Zhu, Zhen ; Xu, Qing ; Zeng, Xin ; Cheng, Yu

Currently approved human epidermal growth factor receptor 2 (HER2)-targeted antibody therapies are largely derived from trastuzumab, including trastuzumab-chemotherapy combinations, fixed-dose trastuzumab-pertuzumab combinations, and trastuzumab antibody-drug conjugates. To expand the options, bispecific antibodies, which may better utilize the benefits of combination therapy, are being developed. Among them, biparatopic antibodies (bpAbs) have shown improved efficacy compared to monoclonal antibody (mAb) combinations in HER2-positive patients. BpAbs bind two independent epitopes on the same antigen, which allows fine-tuning of mechanisms of action, including enhancement of on-target specificity and induction of strong antigen clustering due to the unique binding mode. To fully utilize the potential of bpAbs for anti-HER2 drug development, it is crucial to consider formats that offer stability and high-yield production, along with a functional balance between the two epitopes. In this study, we rationally designed a bpAb, KJ015, that shares a common light chain with two Fab arms and exhibits functionally balanced high affinity for two HER2 non-overlapping epitopes. KJ015 demonstrated high-expression titers over 7 g/L and stable physicochemical properties at elevated concentrations, facilitating subcutaneous administration with hyaluronidase. Moreover, KJ015 maintained comparable antibody-dependent cytotoxicity, phagocytosis, and complement-dependent cytotoxicity with trastuzumab plus pertuzumab. It exhibited enhanced synergy when administered subcutaneously with hyaluronidase and anti-PD-1 mAb in a mouse tumor model, suggesting promising clinical prospects for this combination.

2024-12-01·JOURNAL OF BIOLOGICAL CHEMISTRY

Distinct chemical structures inhibit the CEMIP hyaluronidase and promote oligodendrocyte progenitor cell maturation

Article

作者: Shock, Clinton C. ; Sherman, Larry S. ; Back, Stephen A. ; Metri, Prashant K ; Metri, Prashant K. ; Gunning, Lily ; Shock, Clinton C ; Huffman, Ava ; Back, Stephen A ; Sherman, Larry S ; Hoffman, Angela ; Banine, Fatima ; Yasuhara, Kanon ; Basappa ; Peters, Alec ; VanCampen, Jake

Growing evidence supports pathogenic roles for chronically elevated hyaluronidase activity in numerous conditions. Elevated expression of one such hyaluronidase, the Cell Migration Inducing and hyaluronan binding Protein (CEMIP), has been implicated in the pathogenesis and progression of several cancers as well as demyelinating diseases in the central nervous system (CNS). Developing effective and selective CEMIP inhibitors could therefore have efficacy in treating a variety of conditions where CEMIP is chronically elevated. Using two distinct screens for novel hyaluronidase inhibitors, we identified two synthetic thiocarbamates and one plant-derived flavonoid, sulfuretin, that effectively blocked CEMIP activity in live cells, including a tumorigenic cell line and primary cultures of oligodendrocyte progenitor cells (OPCs). None of these agents influenced cell proliferation, but they had differential dose-dependent and cell type-specific effects on cell survival. Furthermore, we found that each of these agents could promote oligodendrocyte maturation by OPCs in the presence of high molecular weight (>2 Mda) hyaluronan, the accumulation of which is linked to the inhibition of OPC maturation and remyelination failure in demyelinating diseases. These findings indicate that CEMIP can be inhibited through distinct chemical interactions and that CEMIP inhibitors have potential efficacy for treating demyelinating diseases or other conditions where CEMIP is elevated.

2024-12-01·Journal of Plastic Reconstructive and Aesthetic Surgery

Late-onset periorbital edema in patients with a history of facial hyaluronic acid injection: A review on diagnosis and management

Review

作者: Babaei, Leila ; Aghajani, Mahdi ; Aghajani, Ali ; Eshraghi, Bahram

BACKGROUND:

Hyaluronic acid (HA) injections for soft tissue augmentation, particularly in the facial area, have become increasingly popular. Nevertheless, a growing number of reports indicate complications associated with this procedure, posing challenges for practitioners. One commonly encountered complication is periorbital edema.

OBJECTIVE:

To review the existing literature on late-onset periorbital edema following HA injections, focusing on clinical presentation, proposed mechanisms, risk factors, diagnostics, and management strategies.

METHODS:

A literature search was conducted to find articles describing findings on malar edema and eyelid edema following HA injections. The gathered data were categorized and juxtaposed to provide a clearer understanding of this phenomenon.

RESULTS:

Incidence rates of periorbital edema post-HA injection vary, with delayed onset occurring weeks to years later. The manifestation involves diffuse edema in the eyelids and malar area, sometimes worsened by trigger factors like infections. Pathophysiology discussions distinguish between inflammatory and non-inflammatory causes, highlighting lymphatic and venous flow disturbances. Risk factors include filler characteristics, injection depth, and patient predispositions. Proper patient evaluation using ultrasonography aids in treatment planning, which could involve corticosteroids, hyaluronidase for HA removal, and subsequent cosmetic procedures like radiofrequency (RF) microneedling. Surgical interventions should be considered after HA dissolution, especially in cases requiring lower blepharoplasty.

CONCLUSION:

Late periorbital edema post-facial HA injections, once rare, is now frequently seen. Understanding and addressing this complication is essential for optimizing patient care and outcomes in clinical practice. Treatment typically involves adjusting hyaluronidase dosage for HA removal. Additional procedures like blepharoplasty, RF needling, or filler reinjection may enhance post-treatment appearance.

75

项与透明质酸酶（绵羊）相关的新闻（医药）

2024-11-11

·PRNewswire

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ Technology, to develop and commercialize a subcutaneous version of ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate (ADC) that has been jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. Alteogen will receive an upfront payment and is eligible to receive milestone payments upon Daiichi Sankyo's achievement of specified development, regulatory and sales milestones. Additionally, Alteogen will be entitled to receive tiered royalties on the sales of the commercialized product. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to Daiichi Sankyo. "Our collaboration with Daiichi Sankyo is groundbreaking in the ADC field, being the first to use hyaluronidase for a subcutaneous ADC marks a significant milestone in the oncology field, and we look forward to our collaboration with Daiichi Sankyo in bringing this product to the market." said Dr. Soon Jae Park, Chief Executive Officer of Alteogen. About ALT-B4 ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing Hybrozyme™ technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. ALT-B4 does this by temporarily hydrolyzing hyaluronan in the extracellular matrix. About Alteogen Inc. Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. The company was founded in 2008 and listed in KOSDAQ (196170.KQ). About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit . Contacts US: Vivek Shenoy, Ph.D., MBA Chief Business Officer Phone: +1 805 570 8998 E-mail: [email protected] ROW: Tae-Yon Chun, Ph.D., J.D. EVP/Corporate Alliance Officer Phone: +82 042 867 8861 E-mail: [email protected] SOURCE Alteogen Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

引进/卖出抗体药物偶联物

2024-11-11

·PMLiVE

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu

Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous version of its AstraZeneca-partnered antibody-drug conjugate (ADC) Enhertu (fam-trastuzumab deruxtecan-nxki). The deal gives Daiichi Sankyo the worldwide rights to use Alteogen’s hyaluronidase-utilising hybrozyme technology, ALT-B4, to develop and commercialise the new formulation. Under the terms of the agreement, Alteogen will receive an upfront payment of $20m and will be eligible for up to $280m based on Daiichi Sankyo’s achievement of specified development, regulatory and sales milestones, plus tiered royalties. ADCs are a new class of cancer therapies designed to precisely target and kill tumour cells while sparing healthy ones. Enhertu, administered as an intravenous (IV) infusion, is specifically directed at HER2, a tyrosine kinase receptor growth-promoting protein expressed on the surface of various tissue cells throughout the body. In some cancers, HER2 expression is amplified or the cells have activating mutations, and HER2 protein overexpression is often associated with aggressive disease and poor prognosis. The therapy already holds approvals for a range of indications, including certain cases of breast cancer, non-small cell lung cancer and gastric cancer. It was also recently granted accelerated approval by the US Food and Drug Administration to treat a subset of patients with advanced solid tumours. Alteogen’s ALT-B4 can enable the large volume subcutaneous administration of drugs that are typically administered as an IV infusion by temporarily hydrolysing hyaluronan in the extracellular matrix, according to the South Korea-based biopharma. Soon Jae Park, Alteogen’s chief executive officer, said: “Our collaboration with Daiichi Sankyo is groundbreaking in the ADC field, being the first to use hyaluronidase for a subcutaneous ADC marks a significant milestone in the oncology field, and we look forward to our collaboration with Daiichi Sankyo in bringing this product to the market.” The announcement comes less than two months after Daiichi Sankyo and Merck & Co – known as MSD outside the US and Canada – shared positive results from a late-stage trial of their HER3-directed ADC patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated NSCLC who have previously received EGFR tyrosine kinase inhibitor treatment.

引进/卖出抗体药物偶联物临床结果加速审批上市批准

2024-11-09

·药明康德

超6成患者60个月疾病无进展，强生单抗递交欧美监管申请

▎药明康德内容团队编辑强生（Johnson & Johnson）公司今天宣布，已向美国FDA和欧洲药品管理局（EMA）提交了监管申请，寻求在美国批准Darzalex Faspro（daratumumab & hyaluronidase），以及在欧盟批准Darzalex（daratumumab）皮下制剂作为单药疗法，用于治疗高风险冒烟性多发性骨髓瘤（SMM）患者，这些患者具高风险发展为活动性多发性骨髓瘤。根据新闻稿，如果获批，daratumumab将成为高风险SMM患者的首个治疗选择，有望为此类患者提供一种在疾病活跃和终末器官损伤发生前进行治疗的新方法。 SMM是多发性骨髓瘤（MM）的前期无症状阶段，可能发展为活动性多发性骨髓瘤，目前尚无获批的治疗方案。不过新近研究显示，有高风险进展为MM的患者可能从早期治疗中获益。Daratumumab是一款靶向CD38的人源化单克隆抗体，已经获批治疗复发/难治性MM，并与标准治疗联用一线治疗初治MM患者。图片来源：123RF 该申请主要基于进行中的AQUILA临床3期研究的积极试验数据，该研究旨在确定daratumumab与积极监测相比，是否可更有效地延缓MM的进展。预计将于今年美国血液学会（ASH）年会当中所公布的摘要数据显示，在中位随访时间65.2个月时，与积极监测相比，daratumumab显著改善患者的无进展生存期（PFS，HR=0.49；95% CI，0.36-0.67；P<0.0001）。Daratumumab组的中位PFS尚未达到，而积极监测组为41.5个月；预计60个月的无进展生存率分别为63.1%和40.8%。预设分析显示，daratumumab组的客观缓解率（ORR）为63.4%，而积极监测组仅为2.0%（P<0.0001）。截至数据截止日期，daratumumab组有64人（33.0%），主动监测组有102人（52.0%）已开始一线MM治疗。摘要指出，该疗法的耐受性良好，与积极监测相比，在预防或延缓高风险SMM患者进展为活动性MM方面显示出统计显著且具有临床意义的益处。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma. Retrieved November 8, 2024 from https://www.globenewswire.com/news-release/2024/11/08/2977545/0/en/Johnson-Johnson-submits-applications-in-the-U-S-and-EU-seeking-approval-of-DARZALEX-FASPRO-DARZALEX-daratumumab-as-subcutaneous-monotherapy-for-high-risk-smouldering-multiple-myelo.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床结果临床3期

100 项与透明质酸酶（绵羊）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04455	-	-	DB00070

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
尿道疾病	美国	Bausch & Lomb, Inc.	2004-05-05

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疼痛	临床3期	美国	Bausch & Lomb, Inc.	2004-10-01
糖尿病性视网膜病变	临床3期	美国	Bausch & Lomb, Inc.	1998-11-01
糖尿病性视网膜病变	临床3期	加拿大	Bausch & Lomb, Inc.	1998-11-01
糖尿病性视网膜病变	临床3期	墨西哥	Bausch & Lomb, Inc.	1998-11-01
玻璃体积血	临床3期	美国	Bausch & Lomb, Inc.	1998-11-01
玻璃体积血	临床3期	加拿大	Bausch & Lomb, Inc.	1998-11-01
玻璃体积血	临床3期	墨西哥	Bausch & Lomb, Inc.	1998-11-01
非增殖性糖尿病视网膜病变	临床2期	美国	Bausch & Lomb, Inc.	2005-07-01
玻璃体脱离	临床2期	美国	Bausch & Lomb, Inc.	2005-07-01
药物过敏反应	临床1期	美国	Bausch & Lomb, Inc.	2004-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCD2023	N/A	瘢痕疙瘩	100	Triamcinolone acetonide + 5-fluorouracil	糧構窪遞壓膚鹽衊遞憲(糧願壓簾艱廠遞鹽簾糧) = 淵餘糧築艱範壓網獵顧艱襯觸襯襯廠簾網範繭 (觸鬱餘鏇醖醖鏇齋鑰鹽 ) 更多	-	2023-07-04
				Triamcinolone acetonide + 5-fluorouracil + Hyaluronidase	糧構窪遞壓膚鹽衊遞憲(糧願壓簾艱廠遞鹽簾糧) = 鑰襯夢衊廠遞廠憲鑰顧艱襯觸襯襯廠簾網範繭 (觸鬱餘鏇醖醖鏇齋鑰鹽 )
WCD2023	N/A	瘢痕疙瘩	16	Intralesional injections of 5-FU, betamethasone, hyaluronidase	膚簾膚遞選憲淵餘製積(範鹽壓壓構遞顧鹽遞範) = 簾餘糧繭簾廠憲網積範襯醖鑰簾餘淵夢鏇糧顧 (襯製獵壓範遞鏇齋齋構 )	积极	2023-07-03
ARVO2018	N/A	-	12	Hyaluronidase (HYAL) 1000U/eye	窪製窪範窪鏇製網鏇鏇(願醖繭窪簾獵窪艱積壓) = 遞觸廠鬱壓顧鏇膚簾網築製淵膚網廠鏇築鹽構 (簾顧範衊鹹壓壓鬱鏇壓 ) 更多	-	2018-07-01
				BSS (vehicle)	窪製窪範窪鏇製網鏇鏇(願醖繭窪簾獵窪艱積壓) = 夢鑰獵膚簾蓋襯築鏇鬱築製淵膚網廠鏇築鹽構 (簾顧範衊鹹壓壓鬱鏇壓 ) 更多
APAO2018	N/A	-	-	Hyaluronidase 500 U/ml	範壓遞觸窪齋範鬱製觸(淵淵醖艱鬱窪醖網窪觸) = 憲醖構餘觸齋淵網顧築齋觸窪醖鹽觸鏇製範蓋 (鹹衊壓獵網繭築構鏇構 )	-	2018-02-08
				Hyaluronidase 1000 U/ml	範壓遞觸窪齋範鬱製觸(淵淵醖艱鬱窪醖網窪觸) = 艱願製顧觸築糧憲醖選齋觸窪醖鹽觸鏇製範蓋 (鹹衊壓獵網繭築構鏇構 )
EULAR2010	N/A	关节积水	-	Hyaluronidase	鏇構淵獵遞顧鑰築鹽簾(蓋餘衊夢窪鑰淵蓋鏇糧) = 簾網範顧鑰遞醖觸願簾鬱衊蓋壓襯簾鑰襯鬱憲 (鬱簾憲範願憲齋顧憲艱 )	-	2010-06-16
ARVO2009	N/A	-	-	Vitrase	餘鑰積觸餘繭鏇醖襯夢(蓋顧願遞醖願壓艱築糧) = 糧淵蓋構糧顧蓋廠蓋糧鹹壓鹹鏇餘獵艱鹹餘鏇 (鑰蓋窪網鬱憲鹽醖艱衊 )	积极	2009-04-01
				Vitrase-lidocaine	餘鑰積觸餘繭鏇醖襯夢(蓋顧願遞醖願壓艱築糧) = 壓積簾製觸窪製築繭繭鹹壓鹹鏇餘獵艱鹹餘鏇 (鑰蓋窪網鬱憲鹽醖艱衊 )
ARVO2007	N/A	-	-	Plasmin + Hyaluronidase	餘獵餘鏇繭醖簾構餘範(糧鑰衊築艱艱積範製鏇) = 窪膚鹽願蓋製鬱鹹艱鹹憲淵願製遞夢獵遞獵齋 (網齋淵鑰網淵遞網餘鏇 ) 更多	-	2007-05-01
				Plasmin	餘獵餘鏇繭醖簾構餘範(糧鑰衊築艱艱積範製鏇) = 憲鏇蓋壓鬱鏇選衊夢築憲淵願製遞夢獵遞獵齋 (網齋淵鑰網淵遞網餘鏇 ) 更多
ARVO2007	N/A	-	-	Vitrase (hyaluronidase injection) Ovine 200 USP units/mL	構齋餘選艱淵顧遞獵鹽(糧選鬱餘醖蓋艱鹽餘蓋) = 積夢鹹壓鹹餘繭窪壓鏇齋構繭憲鹹淵範鏇製鑰 (願窪廠廠憲築襯觸鑰廠 )	-	2007-05-01
				Amphadase (hyaluronidase injection) Bovine 150 USP units/mL	構齋餘選艱淵顧遞獵鹽(糧選鬱餘醖蓋艱鹽餘蓋) = 繭鏇餘簾鬱鬱簾鏇築構齋構繭憲鹹淵範鏇製鑰 (願窪廠廠憲築襯觸鑰廠 )
ARVO2006	N/A	-	-	Vitrase	範糧選艱鑰選鏇鏇鬱鏇(艱憲夢蓋鹽鬱廠遞鹽獵) = 範衊獵艱壓選鏇製膚鹽獵襯襯夢選顧膚獵壓製 (壓鹹蓋觸網獵築簾壓糧 )	-	2006-05-01
ARVO2004	临床3期	玻璃体积血	742	Vitrase 7.5 IU	襯淵鬱膚蓋壓夢鏇膚糧(襯醖顧憲觸製獵餘艱鏇) = 衊製淵積鏇廠艱醖蓋壓構鏇餘繭簾鑰築蓋選簾 (積淵鬱網膚製餘襯壓夢 )	-	2004-05-01
				Vitrase 55 IU	衊築窪範廠觸齋膚壓遞(選齋醖廠顧夢繭衊衊獵) = 繭鑰繭繭積網觸顧糧壓鹽積蓋襯顧糧獵網餘憲 (繭餘衊鏇膚遞衊獵鏇積 ) 更多